Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 17/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 17/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 16/20 | 1.00 |
| ▸ | CDK2 | P24941 | 16/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 16/20 | 1.00 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.60 |
| ▸ | MGMT | P16455 | 6/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7807591 | 0.88 | CDK1 (0.78) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL9850464 | 0.85 | CDK1 (1.00) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| Methylguanine SCHEMBL231097 | 0.81 | CDK1 (0.69) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| Methylguanine SCHEMBL29903462 | 0.81 | CDK1 (0.69) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8619367 | 0.80 | CDK1 (0.66) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL7985300 | 0.79 | CDK1 (1.00) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8618498 | 0.79 | CDK1 (0.77) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL30176198 | 0.79 | CDK1 (0.77) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL5201806 | 0.79 | CDK1 (0.65) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL31713041 | 0.78 | CDK2 (0.64) | CDK1CCNB1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | claimed |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | claimed |
| EP-3131914-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | Idenix Pharmaceuticals LLC (US) | 2017-02-22 | — | — | EP | claimed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | claimed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | claimed |
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | disclosed |
| EP-3131914-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | Idenix Pharmaceuticals LLC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| CN-1027373-C | Therapeutic nucleosides | WELLCOME FOUND (GB) | 1995-01-11 | — | — | CN | disclosed |
| US-5153318-A | Viricides for hepatitis and human t-cell leukemia/lymphoma viruses | BURROUGHS WELLCOME CO. (US) | 1992-10-06 | — | — | US | disclosed |
| EP-0452680-A1 | Substituted purines, process for their preparation and their use as antiviral agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-10-23 | — | — | EP | disclosed |
| CN-1054982-A | The purine that replaces, its preparation method and as the purposes of antiviral drug | HOECHST AG (DE) | 1991-10-02 | — | — | CN | disclosed |
| CN-1051180-A | The nucleosides that is used for the treatment of | WELLCOME FOUND (GB) | 1991-05-08 | — | — | CN | disclosed |
| EP-0217207-B1 | 2-AMINO PURINES SUBSTITUTED IN POSITIONS 6 AND 9, THEIR USE, MEDICAMENTS CONTAINING THESE PURINES AND PROCESSES FOR THEIR PREPARATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-04-10 | — | — | EP | disclosed |
| EP-0421739-A1 | 3'-azido purine nucleoside | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-04-10 | — | — | EP | disclosed |
| EP-0400686-A1 | 2-Amino-9-[1,3bis-(isopropoxy)-propyl-2-oxymethyl]-purine, its utilization and medicaments containing it | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-12-05 | — | — | EP | disclosed |
| EP-0260596-A2 | 2-Amino-6-alkoxy-purins substituted in position 9, process for their preparation, their use and pharmaceutical compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-03-23 | — | — | EP | disclosed |
| EP-0217207-A1 | 2-Amino purines substituted in positions 6 and 9, their use, medicaments containing these purines and processes for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | CDK1 573/4885CCNB1 1096/4885CCNA2 361/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | CDK1 571/4885CCNB1 1131/4885CCNA2 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.